Kiyatec
Kiyatec develops 3D phenotypic cell-based assays and diagnostic solutions for predicting patient response to cancer drug treatment. The company creates live 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials, and clinical diagnostics. This information helps in drug selection, minimizing clinical trial failures, and maximizing…
Funding snapshot
About
Kiyatec develops 3D phenotypic cell-based assays and diagnostic solutions for predicting patient response to cancer drug treatment. The company creates live 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials, and clinical diagnostics. This information helps in drug selection, minimizing clinical trial failures, and maximizing patient outcomes. Founded in 2005 and headquartered in Pendleton, Kiyatec has raised approximately $29.5M in Series C funding from investors including Esperante, SCRA, Seae Ventures, LabCorp, Bruker, HHS, and Inova. The company's 3D cell culture technology more accurately replicates the in vivo tumor microenvironment compared to traditional 2D cell cultures, providing clinically relevant predictions of how individual patients' tumors will respond to specific chemotherapy regimens, supporting the shift toward personalized oncology treatment.
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA,
Life Sciences Platforms and Tools > Research Assays > Cell Based Assays > Diversified
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.